





Figure 1 (cont.)








Figure 2A (cont.)



TCR	Target	HLA
HN-P32-39	MAGEA1	C*07:02
HN-P32-41		

5/17

Figure 2B




Figure 2C

GREHSAYGEPRKLTQDLVQEKYLEYRQV/PDSDPARYEFWGPRLAETSIVKYLEYVVKV/SARVRRFFPSLREAAAREEGV*SELSP
YLEYRQV/PDSDPARYEFWGPRLAETSIVKYLEYVVKV/SARVRRFFPSLREAAAREEGV*SELSRADPCV**VDYISRDGETHYRT

Figure 2D




Figure 2E




Figure 3A




Figure 3B




Figure 4A

Cell line		MAGEA1 TPM
U266B1	Plasma cell myeloma	657
A101D	Melanoma	359
SKMEL5	Melanoma	8
786-O	Renal cell carcinoma	0.4

Figure 4B




Figure 4C







Figure 5A


Cell line	Disease	MAGEA1 TPM
U266B1	Plasma cell myeloma	657
A101D	Melanoma	359
HS294T	Melanoma	267
A2058	Melanoma	128
NCIH1437	Lung adenocarcinoma	25
HEK-C0702	Embryonic kidney	0


Figure 5B















- TCR 41 T cells co-cultured with HEx cells expressing different MHC Class I alleles






Figure 10




Figure 11

